Corinne Johnson
Stock Analyst at Goldman Sachs
(4.38)
# 1,264
Out of 4,630 analysts
245
Total ratings
56.1%
Success rate
12.7%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintained: Hold | $33 → $37 | $38.41 | -3.67% | 23 | Jul 16, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 | $20.40 | +66.67% | 8 | Jul 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $20 → $23 | $22.82 | +0.79% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Maintained: Sell | $56 → $57 | $103.12 | -44.72% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $158 → $159 | $115.63 | +37.51% | 31 | Jun 14, 2026 | |
| TGTX TG Therapeutics | Maintained: Hold | $41 | $49.76 | -17.60% | 21 | Jun 3, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Hold | $35 → $36 | $37.02 | -2.76% | 11 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $163.41 | +30.35% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $13.50 | +11.11% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Maintained: Buy | $27 → $25 | $14.66 | +70.53% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2.5 | $3.08 | -18.83% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $39.95 | -19.90% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $41 | $36.34 | +12.82% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $102 → $101 | $53.14 | +90.06% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.48 | -32.43% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $82 | $75.10 | +9.19% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $67.82 | -52.86% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $30.84 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.89 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.78 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $7.70 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.9017 | n/a | 14 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.91 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $1.18 | n/a | 1 | Sep 14, 2021 |
Harmony Biosciences Holdings
Jul 16, 2026
Maintained: Hold
Price Target: $33 → $37
Current: $38.41
Upside: -3.67%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $34
Current: $20.40
Upside: +66.67%
Amylyx Pharmaceuticals
Jun 18, 2026
Maintained: Buy
Price Target: $20 → $23
Current: $22.82
Upside: +0.79%
Halozyme Therapeutics
Jun 14, 2026
Maintained: Sell
Price Target: $56 → $57
Current: $103.12
Upside: -44.72%
Rhythm Pharmaceuticals
Jun 14, 2026
Maintained: Buy
Price Target: $158 → $159
Current: $115.63
Upside: +37.51%
TG Therapeutics
Jun 3, 2026
Maintained: Hold
Price Target: $41
Current: $49.76
Upside: -17.60%
IDEAYA Biosciences
Jun 3, 2026
Maintained: Hold
Price Target: $35 → $36
Current: $37.02
Upside: -2.76%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $163.41
Upside: +30.35%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $13.50
Upside: +11.11%
Biohaven
May 28, 2026
Maintained: Buy
Price Target: $27 → $25
Current: $14.66
Upside: +70.53%
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $3.08
Upside: -18.83%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $39.95
Upside: -19.90%
Apr 15, 2026
Maintained: Buy
Price Target: $38 → $41
Current: $36.34
Upside: +12.82%
Mar 16, 2026
Maintained: Buy
Price Target: $102 → $101
Current: $53.14
Upside: +90.06%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.48
Upside: -32.43%
Jan 12, 2026
Maintained: Buy
Price Target: $56 → $82
Current: $75.10
Upside: +9.19%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $67.82
Upside: -52.86%
Jul 18, 2025
Maintained: Buy
Price Target: n/a
Current: $30.84
Upside: n/a
Jul 31, 2024
Maintained: Buy
Price Target: n/a
Current: $3.89
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.78
Upside: n/a
Jun 18, 2024
Maintained: Hold
Price Target: n/a
Current: $7.70
Upside: n/a
Nov 14, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.9017
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $5.91
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $1.18
Upside: n/a